Skip to main content

ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064

Objective

Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant solid tumors, usually after very intensive first-line therapy, curative treatment options are scarce. Preclinical drug testing to identify promising treatment options that match the molecular make-up of the tumor is hampered by the facts that i) molecular genetic data on pediatric solid tumors from relapsed patients and thus our understanding of tumor evolution and therapy resistance are very limited to date and ii) for many of the high-risk entities no appropriate and molecularly well characterized patient-derived models and/or genetic mouse models are currently available. Thus, quality-assured upfront preclinical testing of novel molecularly targeted compounds in a (saturated) repertoire of well-characterized models will establish the basis to increase therapeutic successes of these drugs in children with solid malignancies. Since these tumors are overall genetically much less complex than their adult counterparts, it is anticipated that it will be easier to identify powerful predictive biomarkers to allow for accurate matching of targets and drugs.

To address this high, as yet unmet clinical need, we have formed the ITCC-P4 consortium consisting of academic and commercial partners from 8 European countries and covering the full spectrum of qualifications needed for quality-assured preclinical drug development including expertise in patient derived models, histopathology, in vivo pharmacology, bioinformatics and data management, centralized testing capabilities, medical expertise regarding the entities in question, regulatory knowledge, and project management of large consortia. With this consortium in a public-private partnership with the participating pharma companies we strongly believe to be ideally positioned to greatly expedite the development of more precise and efficacious drugs for children with malignant solid tumors

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/basic medicine/pharmacology and pharmacy

Call for proposal

H2020-JTI-IMI2-2015-07-two-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Address
Im Neuenheimer Feld 280
69120 Heidelberg
Germany
Activity type
Research Organisations
EU contribution
€ 2 995 864

Participants (20)

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
United Kingdom
EU contribution
€ 566 750
Address
Old Brompton Road 123
SW7 3RP London
Activity type
Higher or Secondary Education Establishments
INNOVATIVE THERAPIES FOR CHILDREN WITH CANCER ASSOCIATION
France
EU contribution
€ 107 538
Address
Rue Edouard Vaillant 114
94805 Villejuif
Activity type
Research Organisations
INSTITUT GUSTAVE ROUSSY
France
EU contribution
€ 280 912
Address
Rue Camille Desmoulins 39
94805 Villejuif
Activity type
Research Organisations
ALLEANZA CONTRO IL CANCRO
Italy
EU contribution
€ 133 776
Address
Via Giorgio Ribotta 5
00144 Roma
Activity type
Other
UNIVERSITAT ZURICH
Switzerland
EU contribution
€ 0
Address
Ramistrasse 71
8006 Zurich
Activity type
Higher or Secondary Education Establishments
MEDIZINISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 131 075
Address
Spitalgasse 23
1090 Wien
Activity type
Higher or Secondary Education Establishments
FUNDACIO SANT JOAN DE DEU
Spain
EU contribution
€ 129 050
Address
Calle Santa Rosa, 39-57
08950 Esplugues De Llobregat
Activity type
Research Organisations
EXPERIMENTELLE PHARMAKOLOGIE UND ONKOLOGIE BERLIN-BUCH GMBH
Germany
EU contribution
€ 563 425
Address
Robert-roessle-strasse 10
13125 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
EU contribution
€ 380 300
Address
Meibergdreef 15
1105AZ Amsterdam
Activity type
Higher or Secondary Education Establishments
XENTECH SAS
France
EU contribution
€ 563 425
Address
Rue Pierre Fontaine 4
91000 Evry
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ST. ANNA KINDERKREBSFORSCHUNG
Austria
EU contribution
€ 163 285
Address
Zimmermannplatz 10
1090 Wien
Activity type
Research Organisations
INSTITUT CURIE
France
EU contribution
€ 214 038
Address
Rue D'ulm 26
75231 Paris
Activity type
Research Organisations
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Germany
EU contribution
€ 352 562
Address
Chariteplatz 1
10117 Berlin
Activity type
Higher or Secondary Education Establishments
PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV
Netherlands
EU contribution
€ 788 000
Address
Heidelberglaan 25
3584CS Utrecht
Activity type
Other
Eli Lilly and Company Limited
United Kingdom
EU contribution
€ 0
Address
Lilly House, Priestley Road
RG24 9NL Basingstoke
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
F. HOFFMANN-LA ROCHE AG
Switzerland
EU contribution
€ 0
Address
Grenzacherstrasse 124
4070 Basel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PFIZER LIMITED
United Kingdom
EU contribution
€ 0
Address
Ramsgate Road
CT13 9NJ Sandwich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
BAYER AKTIENGESELLSCHAFT
Germany
EU contribution
€ 0
Address
Kaiser-wilhelm-allee 1
51373 Leverkusen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PHARMAMAR, S.A.
Spain
EU contribution
€ 0
Address
Avda. De Los Reyes , Poligono Industrial La Mina 1
28770 Colmenar Viejo (Madrid)
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH
Germany
EU contribution
€ 0
Address
Am Flughafen 12-14
79108 Freiburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)